Tesamorelin: A Laboratory Research Reference

Tesamorelin is a synthetic peptide in the growth hormone–releasing hormone (GHRH) analogue family, engineered from the sequence of native GHRH. It is studied in laboratory research for its interaction with the GHRH receptor and the downstream promotion of growth hormone release in experimental models.

This page is a non-promotional scientific reference for researchers. It does not provide fat-loss, body-composition, therapeutic, or human-use guidance. Tesamorelin supplied by Bulk Aussie Peptides is for laboratory research purposes only.

Chemical Identity

Tesamorelin is a GHRH analogue built from the 44-amino-acid native hormone, modified to improve stability against enzymatic breakdown. It retains the ability to engage the GHRH receptor, which is the mechanism through which growth hormone release is stimulated in experimental models. Its structure places it in the same GHRH-analogue family as CJC-1295, but with a distinct modification profile.

As a synthetic peptide, tesamorelin is assembled stepwise in the laboratory, then purified and characterised before it is supplied for research. For background on production and verification, see the synthetic peptides research guide.

Receptor Pharmacology

In laboratory models, tesamorelin binds to the GHRH receptor and promotes growth hormone release through the same receptor pathway used by endogenous GHRH.[1] This places it in the GHRH-receptor-agonist class, distinct from ghrelin-receptor secretagogues such as ipamorelin. For a comparison of tesamorelin against the CJC-1295 GHRH analogue, see the tesamorelin versus CJC-1295 comparison.

Molecular Characteristics

• Classification: a growth hormone–releasing hormone (GHRH) analogue.
• Sequence basis: derived from the 44-amino-acid native GHRH with stability-improving modifications.
• Molecular weight: reported in Daltons (Da) and compared against the theoretical sequence-derived mass.
• Physical form: lyophilised (freeze-dried) powder.

Areas of Scientific Research

• GHRH receptor pharmacology: activation and downstream signalling.
• Growth hormone release: stimulation in experimental models.
• GHRH analogue structure: how sequence modifications affect stability and receptor interaction.

These investigations are conducted in vitro or in approved animal research models under institutional oversight.

Analytical Testing

Tesamorelin is characterised using:

• HPLC for purity assessment.
• Mass spectrometry for identity confirmation by molecular mass.

See how to read a peptide Certificate of Analysis for interpretation guidance.

References

• [1] Falutz, J., Mamputu, J.-C., Potvin, D., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus–infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. PubMed 20554713.

Related Research Resources

• Tesamorelin vs CJC-1295 — a detailed comparison.
• Reading a Peptide Certificate of Analysis.

Related Analytical Documentation

The literature above describes tesamorelin research; it is distinct from the batch-specific testing performed on any supplied material. See the Certificate of Analysis library, the batch verification tool, and the testing and quality process.